In recent years, the number of multi-indication drugs in China has grown rapidly, and their medical insurance access and payment standards are facing new challenges. How to better realize the value-based price of multi-indication drugs has become a hot social issue. Based on the available international multi-indication drug access model, this paper explores the method of realizing value-based prices for multi-indication drugs that suit China's conditions.
Key words
multi-indication drug /
value-based price /
payment standard
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Office of Health Economics.Payment Models for Multi-indication Therapies[EB/OL].(2021-11)[2022-03-14].https://www.ohe.org/publications/payment-models-multi-indication-therapies.
[2] Campillo-ArteroC,Puig-JunoyJ,Segú-TolsaJL,etal.Price ModelsforMulti-indicationDrugs:ASystematicReview[J].Appliedhealtheconomicsandhealthpolicy,2020,18(1):47-56.
[3] Pearson SD,Dreitlein WB,Henshall C,etal.Indication-specific pricing of pharmaceuticals in the US health caresystem[J].Journal of Comparative Effectiveness Research,2017,6(5):397-404.
[4] PerssonU,NorlinJM.Multi-indicationand Combination Pricingand Reimbursement of Pharmaceuti-cals:Opportunities for Improved Health Carethrough Faster Uptake of New Innovations[J].Appl Health Econ Health Policy,2018,16(2):157-165.
[5] Office of Health Economics.Multi-indication pricing(MIP):practical solution sand steps to move forward[EB/OL].(2018-11-28)[2022-03-14].https://www.ohe.org/publications/multi-indication-pricing-mip-Practical-solutions-and-steps-move-forward.
[6] 代展菁,薛天祺,向贵圆,等.基于价值定价的多适应症药品医保支付国际经验及启示[J].中国药房,2021,32(02):139-145.
[7] Department of Health&SocialCare.The2019 Voluntary Scheme for Branded Medicines Pricingand Access[EB/OL].(2018-11-28)[2022-03-14].https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761834/voluntary-scheme-for-branded-medicines-pricing-and-access-chapters-and-glossary.pdf.
